Elon Musk's Twitter takeover has been nothing if not tumultuous, and that tumult hit home for pharma Thursday, when an account impersonating Eli Lilly and Company - taking advantage of lax
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh